The Regen BioPharma Inc (OTCMKTS:RGBP) stock has been one of the biggest gainers over the past weeks. However, at the same time, it should also be noted that the stock has been quite volatile.
After having hit record highs recently, the stock slumped by as much as 70%. That being said, the Regen stock is still up by a staggering 1000% since April 8 and hence, it might still be a good idea for investors to keep an eye on the stock.
The stock had rallied strongly earlier on this month after the company announced that it signed a licensing deal with Oncology Pharma for its pancreatic cancer treatment. As per the provisions of the licensing agreement, Oncology is going to get access to the intellectual property owned by Regen in relation to mRNA.
It will then be deployed by Oncology Pharma for creating therapies for pancreatic cancer treatment. It proved to be a significant trigger for the stock and it will be interesting to see if the stock can mount a recovery this week.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.